Lestat R Ali

11PUBLICATIONS
91CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Translation and interpretation studiesTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Feb 26, 2025
Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer.

Ana C Garrido-Castro, Noah Graham, Lestat R Ali

|Jul 11, 2024
Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor.

Paul E Oberstein, Andressa Dias Costa, Emily A Kawaler

|Sep 21, 2023
PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer.

Lestat R Ali, Patrick J Lenehan, Victoire Cardot-Ruffino

|Mar 07, 2023
cIAP1/2 Antagonism Induces Antigen-Specific T Cell-Dependent Immunity.

Katherine S Ventre, Kevin Roehle, Elisa Bello

|Jan 23, 2023
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer.

Lestat R Ali, Ana C Garrido-Castro, Patrick J Lenehan

|May 20, 2021
cIAP1/2 antagonism eliminates MHC class I-negative tumors through T cell-dependent reprogramming of mononuclear phagocytes.

Kevin Roehle, Li Qiang, Katherine S Ventre

Pageof 2

Frequent Collaborators

6 joint publications

Stephanie K Dougan

4 joint publications

Patrick Lenehan

3 joint publications

M Aladdin Bhuiyan

3 joint publications

Shom Goel